INTRODUCTION
Abnormalities of thyroid function in the mother and an increase in maternal-thyroid-stimulating immune globulin (TSI) can lead to fetal and neonatal Graves' disease, a severe, usually transient, derangement of thyroid function. The perinatal mortality rate in this condition (which includes many intrauterine deaths and stillbirths), approaches 25%. 1 We previously reported the successful management of a newborn infant with thyrotoxicosis using the radiocontrast agent iopanoic acid and propranolol 2 and we now report the successful management of five additional cases.
CASE SUMMARIES
The initial maternal and infant clinical and laboratory data are summarized in Table 1 . The maternal age was between 25 and 43 years and maternal TSI levels ranged from 409 to 1431% (normal <130%). Maternal TSI levels >500% are predictive of neonatal Graves' disease. 3 There was a history of Graves' disease in each of the mothers. Three women had developed Graves' disease during the pregnancy and one (the mother of cases 1 and 2) had previously had a thyroid ablation with radioactive iodine and was taking levothyroxine. Antithyroid medication was administered to three women (and transplacentally to their fetuses) during their pregnancies.
Two of the five infants were born before 37 weeks of gestation and case 1 was delivered at 32-6/7 weeks with undiagnosed and untreated fetal hyperthyroidism. Tachycardia was present in three infants and one infant was asymptomatic. Thyroid studies before treatment confirmed the diagnosis of hyperthyroidism (Table 2) . T 4 and T 3 levels were elevated in all infants and TSH was undetected in four.
All infants were treated with propranolol and iopanoic acid. The average mean starting dose of propranolol was 1.7 mg/kg/day, which was then adjusted depending upon the patient response. Iopanoic acid, 250 or 500 mg was given every third or fourth day as per the recommendations of Karpman et al. 4 who administered 3000 mg/1.7m 2 to adults every third day. 4 The duration of treatment was 24 to 94 days based on the infant's clinical response and the time to resolution appears to be directly related to maternal TSI levels (r ¼ 0.914, p<0.05) (Figure 1) . We decreased the dose of propranolol when the resting heart rate was less than 120. Iopanoic acid was decreased at approximately 6 weeks and T 4 and T 3 levels were monitored. If the levels increased, we resumed the previous dose for another 7 to 14 days. TSI levels are useful to gauge therapy, but it may take 10 to 14 days to obtain results. No adverse effects were observed.
The infant with the highest TSI did not normalize T 3 for 50 days, but was clinically asymptomatic and gaining weight normally. This infant was treated for 77 days.
DISCUSSION
The fetal thyroid gland begins to produce thyroid hormone by 18 to 20 weeks of gestation, 5, 6 at which time the maternal TSI that crosses the placenta can stimulate thyroid hormone production. Mothers who have been treated for Graves' disease by surgical or chemical ablation of their thyroid glands, and who are euthyroid, may nevertheless have persistently elevated levels of TSI and thus bear hyperthyroid neonates. Zakarija and McKenzie 3 studied 20 infants with neonatal Graves' disease and found that a maternal TSI greater than 500% basal activity in the third trimester was always associated with a hyperthyroid infant.
The diagnosis of neonatal Graves' disease is based on the maternal history of Graves' disease, the clinical findings in the fetus and neonate, and elevated neonatal T 3 and T 4 levels and a suppressed TSH. Signs of thyrotoxicosis in the fetus include tachycardia, excessive fetal activity, heart failure, and fetal death as early as 24 weeks of gestation. After birth, thyrotoxicosis may present at any time during the first weeks of life. If the mother is receiving antithyroid treatment with a thionamide, enough drug may cross the placenta to delay the onset of symptoms for up to a week. 1 The signs and symptoms of neonatal Graves' disease include irritability, flushing, tachycardia, poor weight gain, weight loss in the face of a lusty appetite, thyroid enlargement, and exophthalmos. Craniosynostosis is a less common complication. These clinical signs may present suddenly and progress rapidly. In normal newborns, there is an abrupt increase in the peripheral conversion of T 4 to T 3 7-9 and, when coupled with a large pool of T 4 available in the hyperthyroid newborn, this phenomenon may contribute to the rapid progression of clinical findings. In the absence of exophthalmos, however, the signs and symptoms can be nonspecific, cardiac arrhythmias and congestive heart failure accounting for the high mortality rate. 1 With proper monitoring, the thyrotoxic fetus can be identified and treated transplacentally with thionamides. The effect of therapy is assessed by using serial ultrasonography to monitor fetal heart rate, growth and goiter development, and fetal thyroid function can be monitored directly using blood sampled by cordocentesis.
The signs of neonatal hyperthyroidism abate over several weeks (typically 6 weeks) as the maternally derived TSI is metabolized. TSI half-life in the infant is approximately 12 days. 4 Iopanoic acid is a negatively charged iodinated molecule. It consists of a benzene ring substituted with three iodine atoms, an amino group, and an isovaleric acid side chain. It was developed for use as a contrast agent to visualize the gallbladder. Both iopanoate and ipodate (a similar radiocontrast agent) inhibit peripheral deiodination of T 4 to T 3 . [10] [11] [12] [13] Iodide molecules are released as iopanoate is degraded, which probably accounts for the observed inhibition of colloid formation and release of T 4 and T 3 from the thyroid. 10, 14, 15 The dose of iopanoic acid was extrapolated from the dose used in adults (3 g/1.7 m 2 every 3 days) as recommended by Karpman et al. 4 Tablets are crushed and spoon fed. The dose (250 to 500 mg) and frequency (every 3 to 4 days) were adjusted based on clinical judgment. We used iopanoic acid because it was immediately available and shares the antithyroid properties of the similar radiocontrast agent, sodium ipodate, which was not available at our hospital.
In contrast to the use of iopanoic acid, standard treatment of neonatal hyperthyroidism has included symptomatic management with sedatives, propranolol, and digitalis as well as antithyroid drugs and/or iodide. Owing to the short half-life of antithyroid medication, this approach to management is cumbersome and inconvenient. Propylthiouracil (PTU) is administered T.I.D., but is unstable in solution and requires pharmacy formulation every 10 days. Furthermore, hypothyroidism is frequently induced with PTU and there is a significant risk of toxic side effects with thionamides including rash, nausea, and agranulocytosis. In addition, correction of the hyperthyroid state with PTU may take a week or more. Nevertheless, whether iopanoic acid or conventional therapy is used, the total duration of therapy is typically 6 to 12 weeks.
No toxic side effects have been reported with iopanoic acid in adults. 2,4,10,11,14 -18 We have observed no toxic effects in infants. Thyroid hormone levels decrease more rapidly 16, 17 and T 3 levels often normalize within 24 to 72 hours. There is no risk of treatment-induced hypothyroidism 4, 14, 16, 17, 19 and the drug is administered every 3 to 4 days as opposed to TID. Since cardiovascular thyrotoxic effects are common in neonates with hyperthyroidism (Table 1) , we recommend propranolol at the time of diagnosis to control or prevent cardiovascular symptoms.
Iopanoic acid does not appear to be adequate therapy for longterm treatment of Graves' disease in all patients 19 but, because the disease is self-limiting in neonates, iopanoic acid is appropriate for the management of neonatal Graves' disease. The radiocontrast agents may prove effective in the management of other causes of transient hyperthyroidism such as thyroxine overdose and subacute thyroiditis 11 and the use of these agents could also be considered in the management of thyroid storm.
